Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:

NCT ID: NCT05657860 Recruiting - Obesity Clinical Trials

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

PWS-GXR
Start date: December 17, 2020
Phase: Phase 4
Study type: Interventional

This is a placebo-controlled clinical trial to assess whether Guanfacine Extended Release (GXR) reduces aggression and self injurious behavior in individuals with Prader Willi Syndrome (PWS). In addition, the study will establish the safety of GXR with a specific focus on metabolic effects.

NCT ID: NCT05653089 Recruiting - Clinical trials for Neurological Disease

Positioning in Wheelchair Bound Patients

AAPO'G
Start date: October 1, 2023
Phase: N/A
Study type: Interventional

The choice of the most suitable chair as well as the improvement of the patient's positioning on this wheelchair is important to limit the discomfort, to prevent the risks of bedsores, the pains related to prolonged sitting and finally to support the interaction of the patient with its environment. The goal of this prospective, longitudinale, monocentric study is to evaluate the impact of standardized positioning in wheelchair-bound patients at risk of slipping. The main questions on the positioning actions are: - their actions impact of positioning actions on shear forces - their impact on sliding in the chair - their impact on the feeling of discomfort in the chair - their impact on the caregivers' feelings about the patient's difficulties (eating, transfers, sliding) Participation in this study will involve an increase in the number of transfers required for shear sheet placement and removal, as well as the time required for ischial measurement and the time to complete the (Tool for Assessing Wheelchair disComfort) TAWC questionnaire.

NCT ID: NCT05652946 Recruiting - Neurologic Disorder Clinical Trials

IISART (International Industry Society of Advanced Rehabilitation Technology) Advanced Rehabilitation Technology Study

Start date: October 17, 2022
Phase: N/A
Study type: Interventional

A pre-post, randomized control trial comparing cost-effective and functional outcomes of participants with neurological diagnoses using robotic devices and advanced technology during inpatient rehabilitation to the outcomes of control participants without the use of robotic devices and advanced technology during rehabilitation. We aim to show at least similar inpatient rehabilitation outcomes and improved health economics in participants with neurological diagnoses by using robotic devices and advanced technology to increase the intensity and dose of rehabilitation.

NCT ID: NCT05645003 Recruiting - Clinical trials for Spinal Cord Injuries

Transcranial Magnetic Stimulation Therapy in Neuropathic Painful Spinal Cord Injury Patients

Start date: November 15, 2022
Phase: N/A
Study type: Interventional

The aim of our study is to investigate the effect of high-frequency Repetitive Transcranial Magnetic Stimulation(rTMS) therapy applied to the dorsolateral PFC (DLPFC) area on neuropathic pain in patients with spinal cord injury. In this area, there are very few studies on the effectiveness of rTMS treatment added to medical treatment in neuropathic pain. In addition, the number of studies comparing the effect of rTMS therapy applied to the DLFPC area is very few.

NCT ID: NCT05626426 Recruiting - Glaucoma Clinical Trials

Electrical Stimulation for the Treatment of Optic Neuropathies

rtACS
Start date: February 27, 2023
Phase: N/A
Study type: Interventional

The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.

NCT ID: NCT05590884 Recruiting - Clinical trials for Central Nervous System Diseases

Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age

Start date: September 21, 2022
Phase: Phase 2
Study type: Interventional

This Phase II open-label, uncontrolled, multicenter trial is designed to investigate the pharmacokinetic (PK) profile of gadopiclenol in plasma, in pediatric patients aged up to 23 months inclusive (term neonates or preterm infants after the neonatal period), using a population PK approach. Primary objective is to evaluate the PK profile of gadopiclenol in plasma following single intravenous injection of 0.05 mmol/kg body weight (BW) in pediatric population aged up to 23 months (inclusive) scheduled for a contrast-enhanced MRI examination of any body region including central nervous system (CNS).

NCT ID: NCT05565833 Recruiting - Alzheimer Disease Clinical Trials

Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)

Start date: February 27, 2023
Phase: Phase 2
Study type: Interventional

This randomized controlled trial will evaluate the impact of an Internet-delivered cognitive behavioral therapy for insomnia (CBT-I) intervention on sleep and the extent to which it contributes to cognitive health in individuals with mild cognitive impairment. Participants with insomnia who meet the study criteria for mild cognitive impairment will be recruited to determine the effects of the CBT-I intervention compared to a patient education condition on sleep and cognition. Internet-based recruitment methods will be used, and outcomes include sleep variables, daytime variables, and cognitive status.

NCT ID: NCT05550402 Recruiting - Asthma Clinical Trials

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)

PARASMA
Start date: February 17, 2024
Phase: N/A
Study type: Interventional

In asthma, the significant role of pathogenesis is chronic airway inflammation, bronchial hyperresponsiveness, and variable airflow obstruction. Asthma with irreversible or fixed airflow obstruction (FAO) is a clinical phenotype resulting from chronic airway inflammation with having longer disease duration, suggesting that airway remodeling contributes to the decline in lung function seen in individuals with asthma. Although this condition frequently occurs in patients with severe asthma, there are pieces of evidence occurring in those with mild to moderate asthma. According to previous research, low lung function, FEV1 less than 60% predicted, is a robust independent predictor of subsequent asthma attacks and other asthma outcomes, including asthma control and SABA use. In a recent study, the patients with mild to moderate asthma who received mild to medium dosed inhaled corticosteroid plus long-acting beta-2 agonist with or without asthma control showed evidence of FAO with or without bronchodilator reversibility. Therefore parasympathetic activity may be affected by FAO in those patients. The autonomic nervous system plays an essential role in asthma, especially from the parasympathetic, promoting bronchoconstriction and regulating airway inflammation and remodeling. This study hypothesizes that a cholinergic mechanism may play a significant role in FAO across patients with mild, moderate, and severe asthma. This might increase the fundamental evidence leading to early-step treatment with anti-cholinergic medication in early asthma severity driven by FAO.

NCT ID: NCT05539781 Recruiting - Clinical trials for Cardiovascular Diseases

Change of Hemodynamics and Cerebral Functions After Carotid Artery Revascularization

HALO
Start date: January 1, 2020
Phase:
Study type: Observational

The majority (>80%) of strokes are of ischemic etiology, of which ≈15% to 20% are attributable to atherosclerosis of the extracranial carotid arteries. The primary goal in carotid artery revascularization is to prevent stroke in patients with carotid artery stenosis. Treatment options including carotid endarterectomy (CEA) and carotid artery stenting (CAS). Hence, the investigators aim to compare carotid artery stenting (CAS) with carotid endarterectomy (CEA) in terms of long-term prognostic endpoints. Also, CEA and CAS result in different postoperative geometric features of carotid arteries that entail relevant modifications of rheological parameters, that may be associated with the risk of local complications and carotid artery restenosis. Finally, long-term and sustained cognitive benefits after carotid artery revascularization need further research and evidence.

NCT ID: NCT05526508 Recruiting - Clinical trials for Neurological Diseases or Conditions

Rebound Exercise in Neurological Disorders

Start date: December 12, 2022
Phase: N/A
Study type: Interventional

This study will be a pretest-posttest interventional trial investigating the use of rebound exercise in community-dwelling individuals with neurological disorders.